Healthcare stocks are holding on to small gains today with the
NYSE Healthcare Sector Index climbing about 0.1% while shares of
healthcare companies in the S&P 500 gaining about 0.4% as a
In company news, Oncolytics Biotech Inc. (
) is up over 21% at $3.22 a share after the development-stage
company reported positive final tumor response data from Phase II
testing of its Reolysin drug candidate in combination with
carboplatin and paclitaxel in patients with squamous cell
The analysis examined best overall tumor responses between
pre-treatment and up to six treatment cycles. Out of 25 evaluable
patients who had more than one cycle of therapy, 23 - or 92% - of
the test subjects exhibited overall tumor shrinkage. Mean shrinkage
In other sector news,
(+) ISIS, Receives $100-mln upfront payment from Biogen Idec (
) as part of multi-year pact to research, develop antisense
technology to treat neurological diseases.
(-) ESRX, Acquires the SmartD Medicare Prescription Drug Plan,
adding around 87,000 covered Medicare patients. Financial terms
were not disclosed.
Copyright (C) 2013 MTNewswires.com. All rights reserved. Unauthorized reproduction is strictly prohibited.